Michael Yeaman: Building Optimism in the Field of Neuromyelitis Optica

Video

Unlike conditions like multiple sclerosis where there is a considerable amount of knowledge and several available approved treatment options that is not the case for neuromyelitis optica. As a result more work is needed to educate patients about what their treatment will be like.

Unlike conditions like multiple sclerosis where there is a considerable amount of knowledge and several available approved treatment options that is not the case for neuromyelitis optica. As a result more work is needed to educate patients about what their treatment will be like.

As a Medical Advisor to the Guthy Jackson Charitable Foundation, Michael R. Yeaman, PhD, has seen the work of the foundation make a big impact in moving the treatment of NMO forward in just a few short years. While it may be a few years before treatments are approved for the treatment of NMO, Yeaman said that is still a brighter picture than patients and their providers had just a few short years ago.

Related Videos
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
Building a Psoriasis Knockout Regimen Around Risankizumab, with Andrew Blauvelt, MD, MBA
Joel Gelfand, MD, MSCE: Phototherapy Utility in Psoriasis
Pediatric Hidradenitis Suppurativa Severity not Linked to Obesity
Rizankizumab and the KNOCKOUT Study, with Andrew Blauvelt, MD, MBA
© 2024 MJH Life Sciences

All rights reserved.